Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Oil magnate’s Venezuela detainment spooks industry - 2Canada Awards C$1.5 Billion Defense Contracts to L3Harris, Airbus
- 3Sahel coups push Africa to top of global democratic declines, report finds
- 423 Most Amusing Messages At any point Sent Among Youngsters and Their Folks
- 5NASA's Apollo 8 moonshot saved 1968. Could Artemis 2 do the same in 2026?
- Dental, Vision, and Hearing Inclusion in Senior Protection.
- As her kidneys fail and time runs short, this activist fights to decriminalize euthanasia in Mexico
- Real time features for Films and Programs
- Countdown to Artemis II: What to know about NASA's moon mission
- What will happen if Artemis 2 astronauts get hit by a solar storm during NASA's ambitious moon mission?
- 23 Most Amusing Messages At any point Sent Among Kids and Their Folks
- Discovery of ancient pleasure boat reveals Egypt's maritime history
- America's Confided in Fridge in 2024
- Exploring the Difficulties of Co-Nurturing: Individual Bits of knowledge
